Billions up for grabs as EU patent on AbbVie’s Humira expiresThe patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a Share XBillions up for grabs as EU patent on AbbVie’s Humira expireshttps://pharmaphorum.com/news/billions-up-for-grabs-as-eu-patent-abbvies-humira-expires/
Sensyne’s gestational diabetes AI app launches on the NHSArtificial intelligence company Sensyne Health has launched a new app that helps women manage gestational diabetes, and five Share XSensyne’s gestational diabetes AI app launches on the NHShttps://pharmaphorum.com/news/sensynes-gestational-diabetes-ai-app-launches-on-the-nhs/
AZ to continue with investment freeze following ‘no deal’ BrexitAstraZeneca will keep manufacturing investments in Britain on hold if the UK’s negotiations with Brussels fail to provide Share XAZ to continue with investment freeze following ‘no deal’ Brexithttps://pharmaphorum.com/news/az-to-continue-with-investment-freeze-following-no-deal-brexit/
Novartis challenges court ruling allowing use of Avastin in wet AMDNovartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Share XNovartis challenges court ruling allowing use of Avastin in wet AMDhttps://pharmaphorum.com/news/novartis-challenges-court-ruling-allowing-use-of-avastin-in-wet-amd/
Deep Lens unveils cancer diagnosis AI tech for pathologistsDigital pathology startup Deep Lens has unveiled an artificial intelligence (AI) platform that will enable pathologists to diagnose Share XDeep Lens unveils cancer diagnosis AI tech for pathologistshttps://pharmaphorum.com/news/deep-lens-unveils-cancer-diagnosis-ai-tech-for-pathologists/
Novo Nordisk poaches AZ’s Helfgott to run Biopharm businessNovo Nordisk has poached a top executive from AstraZeneca, tasking Ludovic Helfgott to lead development of its haemophilia Share XNovo Nordisk poaches AZ’s Helfgott to run Biopharm businesshttps://pharmaphorum.com/news/novo-nordisk-poaches-azs-helfgott-to-run-biopharm-business/
Merck KGaA’s BTK drug reduces lesions in relapsing MS patientsGermany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) Share XMerck KGaA’s BTK drug reduces lesions in relapsing MS patientshttps://pharmaphorum.com/news/merck-kgaas-btk-drug-reduces-lesions-in-relapsing-ms-patients/
BMS Opdivo fails in small cell lung cancerBristol-Myers Squibb has said its Opdivo immunotherapy has failed to improve on standard of care in patients with Share XBMS Opdivo fails in small cell lung cancerhttps://pharmaphorum.com/news/bms-opdivo-fails-in-small-cell-lung-cancer/
BMS invests $12m in cancer immunotherapy tie-up with CompugenBristol-Myers Squibb has invested $12 million in Compugen, a biotech that is investigating a new approach that could Share XBMS invests $12m in cancer immunotherapy tie-up with Compugenhttps://pharmaphorum.com/news/bms-invests-12m-in-cancer-immunotherapy-tie-up-with-compugen/
Allogene astounds Wall Street with $324m IPO to fund cell therapy R&DGreat things were expected of Allogene Therapeutics’ IPO this week – the company is led by Arie Belldegrun Share XAllogene astounds Wall Street with $324m IPO to fund cell therapy R&Dhttps://pharmaphorum.com/news/allogene-astounds-wall-street-with-324m-ipo-to-fund-cell-therapy-rd/
Sandoz free to launch Humira biosimilar following AbbVie dealNovartis’ generics and biosimilars arm, Sandoz, has confirmed it is to launch its biosimilar of AbbVie’s Humira (adalimumab) Share XSandoz free to launch Humira biosimilar following AbbVie dealhttps://pharmaphorum.com/news/sandoz-free-to-launch-humira-biosimilar-following-abbvie-deal/
Ionis and Roche to develop RNAi AMD drug in $760m dealIonis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug Share XIonis and Roche to develop RNAi AMD drug in $760m dealhttps://pharmaphorum.com/news/ionis-and-roche-to-develop-rnai-amd-drug-in-760m-deal/
Novartis launches digital health innovation lab the Novartis BiomeNovartis has launched a digital health innovation lab network named the Novartis Biome to accelerate its digital evolution. The Share XNovartis launches digital health innovation lab the Novartis Biomehttps://pharmaphorum.com/digital/novartis-biome-digital-health-innovation/
Number of UK clinical trials in decline since Brexit voteOngoing uncertainty and concern about Brexit has already cut the number of clinical trials carried out in the Share XNumber of UK clinical trials in decline since Brexit votehttps://pharmaphorum.com/news/number-of-uk-clinical-trials-in-decline-since-brexit-vote/
AI app aims to improve health in developing worldAn app based around artificial intelligence (AI) aims to help patients in countries with developing healthcare systems understand Share XAI app aims to improve health in developing worldhttps://pharmaphorum.com/news/ai-app-aims-to-improve-health-in-developing-world/
FDA gives go-ahead for CRISPR-based sickle cell disease trialDevelopment of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can Share XFDA gives go-ahead for CRISPR-based sickle cell disease trialhttps://pharmaphorum.com/news/fda-gives-go-ahead-for-crispr-based-sickle-cell-disease-trial/
Celltrion/Teva Rituxan biosimilar edges closer to US approvalIt looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in Share XCelltrion/Teva Rituxan biosimilar edges closer to US approvalhttps://pharmaphorum.com/news/celltrion-teva-rituxan-biosimilar-edges-closer-to-us-approval/
EU regulators review Janssen’s esketamine nasal spray antidepressantAn application for Janssen’s investigative nasal ketamine-based antidepressant is under review in Europe. Janssen, which is Johnson & Share XEU regulators review Janssen’s esketamine nasal spray antidepressanthttps://pharmaphorum.com/news/eu-regulators-review-janssens-esketamine-nasal-spray-antidepressant/
An Interview with Alexander Zuern, Device Testing Manager, from Novartis Share XAn Interview with Alexander Zuern, Device Testing Manager, from Novartishttps://pharmaphorum.com/partner-content/an-interview-with-alexander-zuern-device-testing-manager-from-novartis/
Preliminary Attendee List Released for Orphan Drugs & Rare Diseases Conference Share XPreliminary Attendee List Released for Orphan Drugs & Rare Diseases Conferencehttps://pharmaphorum.com/partner-content/preliminary-attendee-list-released-for-orphan-drugs-rare-diseases-conference/
Spotlight sessions at the upcoming Lyophilization USA Conference Share XSpotlight sessions at the upcoming Lyophilization USA Conferencehttps://pharmaphorum.com/partner-content/spotlight-sessions-at-the-upcoming-lyophilization-usa-conference/
Exclusive Speaker Interview with Brent Cezairliyan for SMi’s Superbugs & Superdrugs USA Share XExclusive Speaker Interview with Brent Cezairliyan for SMi’s Superbugs & Superdrugs USAhttps://pharmaphorum.com/partner-content/exclusive-speaker-interview-with-brent-cezairliyan-for-smis-superbugs-superdrugs-usa/
Carina Schey, University of Groningen, Orphan Drugs & Rare Diseases Chair Invitation Share XCarina Schey, University of Groningen, Orphan Drugs & Rare Diseases Chair Invitationhttps://pharmaphorum.com/partner-content/carina-schey-university-of-groningen-orphan-drugs-rare-diseases-chair-invitation/
Corporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communications Share XCorporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communicationshttps://pharmaphorum.com/partner-content/corporate-communications-chief-of-astellas-jo-taylor-moves-to-cello-health-communications/
